Pharmacogenomics for the treatment of dementia

References

• Cacabelos R. Handbook of Neuro geriatrics. Alzheimer disease and other dementias. Epidemiology and Genetics. Barcelona: Masson; 1999.
   Google Scholar
• Cacabelos R. Psychogeriatric research. A conceptual intro-duction to geriatric neuroscience. Psychogeriatrics 2001; 1: 158–88.
   Google Scholar
• Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriat Psychiat 1999; 14: 3–47.
   PubMed Web of Science ®Google Scholar
• Wimo A, jrinsson B, Karlsson G, Winblad B. Health economics of dementia. Chichester: Wiley; 1998.
   Google Scholar
• Selkoe DJ Alzheimer 's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741–66.
   PubMed Web of Science ®Google Scholar
• Price DL, Sisodia SS. mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998; 21: 479–505.
   PubMed Web of Science ®Google Scholar
• Hardy J, Gwinn-Hardy K. Genetic classification of primary degenerative disease. Science 1998; 282: 1075–9.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Nordberg A, Caamario J, Franco-Maside A, Fernandez-Novoa L, G6mez MJ, et al. Molecular strategies for the first generations of antidementia drugs (I). Tacrine and related compounds. Drugs Today 1994; 30: 295–337.
   Google Scholar
• Cacabelos R, Alvarez XA, Lombardi V, Fernandez-Novoa L, Corzo L, Perez P, et al. Pharmacological treatment of Alzheimer's disease: From psychotropic drugs and cholines-terase inhibitors to pharmacogenomics. Drugs Today 2000; 36: 415–99.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Dementia. In: Jobe TH, Gaviria M, Kovilpar- ambil A, eds. Clinical Psychiatry. Massachusetts: Blackwell Science; 1997: 73–122.
   Google Scholar
• Cacabelos R. Diagnosis of Alzheimer's disease: defining genetic profiles (genotype versus phenotype). Acta Neurol Scand 1996; Suppl. 165: 72–84.
   Google Scholar
• Braak H, Braak E, Bohl J. Neuropathology of the cerebral cortex in Alzheimer's disease. Ann Psychiatry 1994; 4: 39–56.
   Google Scholar
• Terry RD, Katzman R. Life span and synapses: will there be a primary senile dementia? Neurobiol Aging 2001; 22: 347–8.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. New strategies for Alzheimer's disease treat- ment: Pleiotropic drugs and multifactorial intervention. In: Giacobini E, Becker R, eds. Alzheimer's Disease: therapeutic strategies. Boston: Birkhauser; 1994: 493–8.
   Google Scholar
• Venter JC, Adams MD, Myers EW, Li PW, Mural R, Sutton GG, et at The sequence of the human genome. Science 2001; 291: 1304–51.
   PubMed Web of Science ®Google Scholar
• International Human Genome Sequencing Consortium. Initial sequence and analysis of the human genome. Nature 2001; 409: 860–921.
   PubMed Web of Science ®Google Scholar
• International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928–33.
   PubMed Web of Science ®Google Scholar
• Schoemaker DD, Schadt EE, Armour CD, He YD, Garrett-Engele P, McDonagh PD, et al. Experimental annotation of the human genome using microarray technol-ogy. Nature 2001; 409: 922–7.
   PubMed Web of Science ®Google Scholar
• Emahazion T, Feuk L, Jobs M, Sawyer SL, Fredman D, St. Clair D, et al. SNP association studies in Alzheimer's disease highlight problems for complex disease analysis. Trends Genet 2001; 17: 407–13.
   PubMed Web of Science ®Google Scholar
• Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355: 1358–61.
   PubMed Web of Science ®Google Scholar
• Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857–65.
   PubMed Web of Science ®Google Scholar
• Chapman PF, Falinska AM, Knevett SG, Ramsay ME Genes, models and Alzheimer's disease. Trends Genet 2001; 17: 254–61.
   PubMed Web of Science ®Google Scholar
• Lombardi VRM, Garcia M, Cacabelos R. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J Neurosci Res 1998; 54: 539–53.
   PubMed Web of Science ®Google Scholar
• Lombardi VRM, Garcia M, Cacabelos R. Genotype_ specific microglial response in cell culture system for the identification of novel therapeutic compounds in Alzheimer's disease and neurimmune disorders. Ann Psychiatry 1999; 7: 157–70.
   Google Scholar
• Lombardi VR, Garcia M, Rey L., Cacabelos R. Character-ization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease individuals. J Neuroimmunol 1999; 97: 163–71.
   Google Scholar
• Cacabelos R. Pharmacogenomics in Alzheimer's disease. Min Rev Med Chem 2002; 2: 59–84.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Alvarez A, Fernandez-Novoa L, Lombardi VRM. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol Scand 2000; Suppl. 176: 12–9.
   Google Scholar
• Tanzi RE, Kovacs DM, Kim TV/, Moir RD, Guenette SY, Wasco W. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 1996; 3: 159–68.
   PubMed Web of Science ®Google Scholar
• Schellenberg GD, D'Souza I, Poorkaj P. The genetics of Alzheimer's disease. Curr Psychiatry Rep 2000; 2: 158–64.
   PubMedGoogle Scholar
• Farrer LA, Myers RH, Connor L, Cupples LA, Growdon JH Segregation analysis reveals evidence of a major gene for Alzheimer's disease. Am J Hum Genet 1991; 48: 1026–33.
   PubMed Web of Science ®Google Scholar
• McKusick VA. Mendelian inheritance in Man. 12th edn. Baltimore: Johns Hopkins University Press; 1998.
   Google Scholar
• Esler WP, Wolfe MS. A portrait of Alzheimer secretases - new features and familiar faces. Science 2001; 293: 1449–54.
   PubMed Web of Science ®Google Scholar
• Goate A, Charner-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704–6.
   PubMed Web of Science ®Google Scholar
• Schellenberg GD, Anderson L, O'dahl S, Wisjman E, Sadovnick AD, Ball MJ, et al. APP(717), APP(693), and PRIP gene mutations are rare in Alzheimer's disease. Am J Hum Genet 1991; 49: 511–7.
   PubMed Web of Science ®Google Scholar
• Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991; 254: 97–9.
   PubMed Web of Science ®Google Scholar
• Chartier-Harlin M-C, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, et at. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991; 353: 844–6.
   PubMed Web of Science ®Google Scholar
• Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene of the N-terminus of beta-amyloid. Nat Genet 1992; 1: 345–7.
   PubMed Web of Science ®Google Scholar
• Eckman CB, Media ND, Crook R, Pérez-Tur J, Prihar G, Pfeiffer E, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A-beta-42(43). Hum Mol Genet 1997; 6: 2087–9.
   PubMed Web of Science ®Google Scholar
• De Jonghe C, Zehr, C, Yager D, Prada CM, Younkin S, Hendriks L, et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis 1998; 5: 281–6.
   PubMed Web of Science ®Google Scholar
• Miravalle L, Tokuda, T, Chiarle R, Giaccone G, Bugiani O, Tagliani F, et at Substitutions at codon 22 of Alzheimer's A-beta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000; 275: 27110–6.
   PubMed Web of Science ®Google Scholar
• Cordell B. 13-Amyloid formation as a potential therapeutic target for Alzheimer's disease. Annu Rev Pharmacol Toxicol 1994; 34: 69–89.
   PubMed Web of Science ®Google Scholar
• Vassar R, Bennet BD, Babu-Khan S, Khan S, Mendiaz EA, Dents P, et al. I3-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–41.
   PubMed Web of Science ®Google Scholar
• Saunders AJ, Kim T-W, Tanzi RE. BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down's syndrome region of chromosome 21. Science 1999; 286: 1255.
   Google Scholar
• Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain A-beta by neprilysin. Science 2001; 292: 1468.
   Web of Science ®Google Scholar
• Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, et al. Beta-amyloid-induced neuronal apop-tosis requires c-Jun N-terminal kinase activation. J Neuro- chem 2001; 77: 157–64.
   PubMed Web of Science ®Google Scholar
• Kajkowski EM, Lo CF, Ning X, Walker S, Sofia HJ, Wang W, et al. Bet a-amyloid peptide-induced apoptosis regulated by a novel protein containing a G protein activation module. J Biol Chem 2001; 271: 18748–56.
   Google Scholar
• Shimohama S. Apoptosis in Alzheimer's disease - an update. Apoptosis 2000; 5: 9–16.
   PubMed Web of Science ®Google Scholar
• Raina AK, Hochman A, Zhu X, Rottkamp CA, Nuno- mura A, Siedlak SL, et at. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (Berl) 2001; 101: 305–10.
   Google Scholar
• Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer's-disease-like pathology in the PDAPPP mouse. Nature 1999; 400: 173–7.
   PubMed Web of Science ®Google Scholar
• St. George-Hyslop P, Haines J, Rogaev E, Mortilla M, Vaula G, Pericak-Vance M, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet 1992; 2: 330–4.
   PubMed Web of Science ®Google Scholar
• Van Broeckhoven C, Backhovens H, Cruts M, De Winter G, Bruyland M, Cras P, et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromo-some 14q24.3. Nat Genet 1992; 2: 335–9.
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et at. Candidate gene for chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973–7.
   PubMed Web of Science ®Google Scholar
• Sherrington R, Rogaev El, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et at Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754–60.
   PubMed Web of Science ®Google Scholar
• Alzheimer's Disease Collaborative Group. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 1995; 11: 219–22.
   Google Scholar
• Rogaev El, Sherrington R, Wu C, Levesque G, Liang Y, Rogaeva EA, et at Analysis of the 5' sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer's disease. Genomics 1997; 40: 415–24.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Beyer K, Lao JI, Mesa MD, Fernandez- Novoa L. Association of genetic risk factors in Alzheimer's disease and a novel mutation in the predicted TM2 domain of presenilin-2 in late-onset AD. In: Iqbal K, Swaab DF, Winblad B, Wisniewslci HM, eds. Alzheimer's Disease and Related Disorders. Chichester: Wiley; 1999: 93–102.
   Web of Science ®Google Scholar
• Cruts M, van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum Mutat 1998; 11: 183–90.
   PubMed Web of Science ®Google Scholar
• Haass C, De Strooper B. The presenilins in Alzheimer's disease-Proteolysis holds the key. Science 1999; 286: 916–9.
   PubMed Web of Science ®Google Scholar
• Lamb BT. Presenilins, amyloid-beta and Alzheimer's disease. Nat Med 1997; 3: 28–9.
   PubMed Web of Science ®Google Scholar
• Mattson Mg Guo Q. The presenilins. Neuroscientist 1999; 5: 112–24.
   Google Scholar
• Scheper W, Annaert W, Cupers P, Saftig P, De Strooper B. Function and dysfunction of the presenilins. Alzheimer Report 1999; 2: 73–81.
   Google Scholar
• Annaert W, De Strooper B. Presenilins: molecular switches between proteolysis and signal transduction. Trends Neuro-sci 1999; 22: 439–43.
   PubMed Web of Science ®Google Scholar
• Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch/g1p-1 signal transduction and beta-APP processing. Nature 2000; 407: 48–54.
   PubMed Web of Science ®Google Scholar
• Choi EK, Zaidi NF, Miller JS, Crowley AC, Marian DE, Lillichook C, et al. Calsenilin is a substrate for caspase-3 that preferentially interacts with the familial Alzheimer's disease-associated C-terminal fragment of presenilin 2. J Biol Chem 2001; 276: 19197–204.
   PubMed Web of Science ®Google Scholar
• Jo DG, Kim MJ, Choi YH, Kim IK, Song YH, Woo HN, et al. Pro-apoptotic function of calsenilin/DREAM/KChIP3. FASEB J 2001; 15: 586–91.
   PubMed Web of Science ®Google Scholar
• Lamb BT, Bardel KA, Kuhiane LS, Anderson JJ, Holtz G, Wagner SL, et al. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat Neurosci 1999; 2: 695–7.
   PubMed Web of Science ®Google Scholar
• Chui D-H, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda 0, et at Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 1999; 5: 560–4.
   Google Scholar
• Wragg M, Hutton M, Talbot C. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease: Alzheimer's Disease Colla-borative Group. Lancet 1996; 347: 509–12.
   PubMed Web of Science ®Google Scholar
• Romas SN, Mayeux R, Tang M-X, Lantigua R, Medrano M, Tycko B, et al. No association between a presenilin 1 polymorphism and Alzheimer disease. Arch Neurol 2000; 57: 699–702.
   PubMedGoogle Scholar
• Roses AD, Strittmatter WJ, Pericalc-Vance MA, Corder EH, Saunders AM, Schmechel DE. Clinical application of apolipoprotein F. genotyping to Alzheimer's disease. Lancet 1994; 343: 1564–5.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Lao JI, Beyer K, Alvarez XA, Franco-Maside A. Genetic testing in Alzheimer's disease: APOE genotyping and etiopathogenic factors. Methods Find Exp Clin Pharma-col 1996; 18 (Suppl. A): 161–78.
   Google Scholar
• Cacabelos R, Santamaria JL. Hypertension and dementia. Etiopathogenic mechanisms and genetic factors. Hipertesion Clinica 2001; 3: 626–59.
   Google Scholar
• Saunders AM, Schmader K, Breitner JCS, Benson MD, Brown WT, Goldfarb L, et at Apolipoprotein F. epsilon-4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993; 342: 710–1.
   PubMed Web of Science ®Google Scholar
• Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance M, Joo SH, et al. Association of apolipoprotein F. allele 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467–72.
   PubMed Web of Science ®Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dosage of apolipoprotein F. type 4 allele and risk of Alzheimer's disease in late onset families. Science 1993; 261: 921–3.
   PubMed Web of Science ®Google Scholar
• Beyer K, Lao JI, Alvarez XA, Cacabelos R. Different implications of APOE E4 in Alzheimer's disease and vascular dementia in the Spanish population. Alzheimer Res 1996; 2: 215–20.
   Google Scholar
• Beyer K, Lao JI, Cacabelos R. Molecular genetics and genotyping in Alzheimer's disease. Ann Psychiatry 1996; 6: 173–87.
   Google Scholar
• Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et at Protective effect of apolipoprotein F. type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180–4.
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Roses AD. Apolipoprotein F. and Alz- heimer disease. Proc Natl Acad Sci USA 1995; 92: 4724–7.
   Web of Science ®Google Scholar
• Olichney JM, Hansen LA, Galasko D, Sayito T, Hostetter CR, Katzman R, et at. The apolipoprotein F. epsylon-4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996; 47: 190–6.
   PubMed Web of Science ®Google Scholar
• Polviko ski T, Sullcava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al. Apolipoprotein F., dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995; 333: 1242–7.
   PubMed Web of Science ®Google Scholar
• Lambert J-C, Mann D, Goumidi L, Harris J, Amouyel P, Iwatsubo T, et at Effect of the APOE promoter polymorph- ism on cerebral amyloid peptide deposition in Alzheimer's disease. Lancet 2001; 357: 608–9.
   PubMed Web of Science ®Google Scholar
• Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. Apolipoprotein F. modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 2001; 11: 107–13.
   Google Scholar
• Saunders AM. Apolipoprotein F. and Alzheimer disease: an update on genetic and functional analysis. J Neuropathol Exp Neurol 2000; 59: 751–8.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Sugihara S, Ogawa A, Oshima N, Ihara Y. Alzheimer beta amyloid deposition enhanced by APOE epsilon 4 gene precedes neurofibrillary pathology in the frontal association cortex of non-demented senior subjects. J Neuropathol Exp Neurol 2001; 60: 731–9.
   PubMed Web of Science ®Google Scholar
• Bennet C, Crawford F, Osborne A, Diaz P, Hoyne J, Lopez R, et at. Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's disease but is not causative. Am J Med Genet 1995; 60: 1–6.
   PubMed Web of Science ®Google Scholar
• Hutton M. Molecular genetics of chromsome 17 tauopathies. Ann NY Acad Sci 2000; 920: 63–73.
   PubMed Web of Science ®Google Scholar
• Forman MS, Lee VM, Trojanowski JQ. New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. J Chem Neuroanat 2000; 20: 225–44.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998; 21: 428–33.
   PubMed Web of Science ®Google Scholar
• Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Mol Brain Res 1986; 1: 271–80.
   Google Scholar
• Donlon TA, Harris P, Neve RL. Localization of micro- tubule-associated protein tau (MTBT1) to chromosome 17q21. Cytogenet Cell Genet 1987; 46: 607.
   Google Scholar
• Goedert M, Spillantini MG, Crowther RA, Chen SG, Parchi P, Tabaton M, et al. Tau gene mutation in familial progressive subcortical gliosis. Nat Med 1999; 5: 454–7.
   Google Scholar
• Kamboh MI, Sanghera DK, Ferrell R, DeKosky ST. APOE*4-associated Alzheimer's disease risk is modified by alpha-1-antichymotrypsin polymorphism. Nat Genet 1995; 10: 486–8.
   Google Scholar
• Tysoe C, Gafinsky D, Robinson D, Brayne CE, Easton DF, Huppert FA, et al. Analysis of alpha-1 antichymotrypsin, presenilin-1, angiotensin-converting enzyme, and methylene- tetrahydrofolate reductase loci as candidates for dementia. Am J Med Genet 1997; 74: 207–12.
   PubMed Web of Science ®Google Scholar
• Lamb H, Christie J, Singleton AB, Leake A, Perry RH, Ince PG, et al. Apolipoprotein F and alpha-1-antichymo-trypsin polymorphism genotyping in Alzheimer's disease and in dementia with Lewy bodies. Distinctions between diseases. Neurology 1998; 50: 388–91.
   PubMed Web of Science ®Google Scholar
• McIlroy SP, Crawford VLS, Dynan KB, McGleenon BM, Vahidassr MD, Lawson J, et al. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J Med Genet 2000; 37: 182–5.
   PubMed Web of Science ®Google Scholar
• Wiebusch H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergistic association between APOE epsilon-4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999; 104: 158–63.
   PubMed Web of Science ®Google Scholar
• Prince JA, Feuk L, Swayer SL, Gottfries J, Ridcsten A, Nagga K, et al. Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet 2001; 9: 437–44.
   PubMed Web of Science ®Google Scholar
• Bertram L, Blacker D, Crystal A, Mullin K, Keeney D, Jones J, et al. Candidate genes showing no evidence for association or linkage with Alzheimer's disease. Exp Ger-ontol 2000; 35: 1353–61.
   PubMed Web of Science ®Google Scholar
• Lehmann DJ, Nagy Z, Litchfield S, Borja MC, Smith AD. Association of butyrylcholinesterase K variant with cholines-terase-positive neuritic plaques in the temporal cortex in late- onset Alzheimer's disease. Hum Genet 2000; 106: 447–52.
   PubMed Web of Science ®Google Scholar
• Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RCP, et at Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19: 357–60.
   PubMed Web of Science ®Google Scholar
• Rogaeva EA, Premkumar S, Grubber J, Serneels L, Scott WK, Kawarai T, et al. An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet 1999; 22: 19–21.
   PubMed Web of Science ®Google Scholar
• Gibson AM, Singleton AB, Smith G, Woodward R, McKeith IG, Perry RH, et al. Lack of association of the alpha-2-macroglobulin locus on chromosome 12 in AD. Neurology 2000; 54: 433–8.
   PubMed Web of Science ®Google Scholar
• Crawford F, Town T, Freeman M, Schinka J, Gold M, Duara R, et al. The alpha-2-macroglobulin gene is not associated with Alzheimer's disease in a case-control study. Neurosci Lett 1999; 270: 133–6.
   PubMed Web of Science ®Google Scholar
• McIlroy SP, Dynan KB, Vahidassr DJ, Lawson JT, Patterson CC, Passmore P. Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer's disease in Northern Ireland. Am J Med Genet 2001; 105: 502–6.
   PubMed Web of Science ®Google Scholar
• Dodel RC, Du Y, Bales KR, Gao F, Eastwood B, Glazier B, etAlpha-2-macroglobulin and the risk of Alzheimer's disease. Neurology 2000; 54: 438–42.
   PubMed Web of Science ®Google Scholar
• Hyman BT, Strickland D, Rebeck GW. Role of the low- density lipoprotein receptor-related protein in 13-amyloid metabolism and Alzheimer's disease. Arch Neurol 2000; 57: 646–50.
   PubMed Web of Science ®Google Scholar
• Rebeck GW, Moir RD, Mw S, Strickland DK, Tanzi RE, Hyman BT. Association of membrane-bound amyloid precursor protein APP with the apolipoprotein F. receptor LRP. Mol Brain Res 2001; 87: 238–45.
   PubMedGoogle Scholar
• Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's disease amyloid-ss(1-40) peptide from the brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489–99.
   PubMed Web of Science ®Google Scholar
• Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, et al. Modulation of beta-amyloid precursor protein processing by low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem 2000; 275: 7410–5.
   PubMed Web of Science ®Google Scholar
• Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, et al. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein F. in a Caucasian population. Neurosci Lett 1997; 222: 187–90.
   PubMed Web of Science ®Google Scholar
• Wavrant-DeVriez e F, Perez-Tur J, Lambert JC, Frigard B, Pasquier F, Delacourte A, et al. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci Lett 1997; 227: 68–70.
   PubMed Web of Science ®Google Scholar
• Hollenbach E, Ackermann S, Hyman BT, Rebeck GW. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease. Neurology 1998; 50: 1905–7.
   PubMed Web of Science ®Google Scholar
• Kamboh MH, Ferrell RE, DeKosky ST. Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoproptein receptor-related protein gene. Neurosci Lett 1998; 244: 65–8.
   PubMed Web of Science ®Google Scholar
• McIlroy SP, Dynan KB, Vahidassr DJ, Lawson JT, Patterson CC, Passmore P. Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer's disease in Northern Ireland. Am J Med Genet 2001; 105: 502–6.
   PubMed Web of Science ®Google Scholar
• Scott WK, Yamaoka LH, Bass MP, Gasket! PC, Conneally PM, Small GW, et al. No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer's disease. Neurogenetics 1998; 1: 179–83.
   PubMed Web of Science ®Google Scholar
• Baum L, Wiebusch H, Pang CP. Roles for lipoprotein lipase in Alzheimer's disease: an association study. Microsc Res Tech 2000; 50: 291–6.
   PubMed Web of Science ®Google Scholar
• Pericalc-Vance MA, Bass MP, Yamaoka LH, Gasket! PC, Scott WK, Terwedow HA, et al. Complete genomic screen in late-onset Alzheimer's disease: evidence for a new locus on chromosome 12. JAMA 1997; 278: 1237–41.
   PubMed Web of Science ®Google Scholar
• Leherov IM, Koldamova RP, Lazo J.S. Human bleomycin hydrolase regulates the secretion of amyloid precursor protein. FASEB J 2000; 14: 1837–47.
   PubMed Web of Science ®Google Scholar
• Montoya SE, Aston CE, DeKosky ST, Kamboh MI, Lazo JS, Ferrell RE. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat Genet 1998; 18: 211–2.
   PubMed Web of Science ®Google Scholar
• Farrer LA, Abraham CR, Haines JL, Rogaeva EA, Song Y, McGraw WT, et al. Association between bleomycin hydro-lase and Alzheimer's disease. Ann Neurol 1998; 44: 808–11.
   PubMed Web of Science ®Google Scholar
• Trower MK, Orton SM, Purvis IJ, Sanseau P, Riley J, Christodoulou C, et al. Conservation of synteny between the genome of the pufferfish (Fugu rubripes) and the region on human chromosome 14 (14q24.3) associated with familial Alzheimer's disease (AD3 locus). Proc Nat Acad Sci USA 1996; 93: 1366–9.
   PubMed Web of Science ®Google Scholar
• Rogaev El, Lukiw WJ, Vaula G, Haines JL, Rogaeva EA, Tsuda T, et al. Analysis of the c-FOS gene on chromosome 14 and the promoter of the amyloid precursor protein gene in familial Alzheimer's disease. Neurology 1993; 43: 2275–9.
   PubMed Web of Science ®Google Scholar
• Nishiwaki Y, Kamino K, Yoshiiwa A, Sato N, Tateishi K, Takeda M, et at T/G polymorphism at intron 9 of presenilin 1 gene is associated with, but not responsible for sporadic late-onset Alzheimer's disease in Japanese population. Neurosci Lett 1997; 227: 123–6.
   PubMed Web of Science ®Google Scholar
• Cruts M, Backhovens H, Martin JJ, van Broeckhoven C. Genetic analysis of the cellular oncogene fos in patients with chromosome 14 encoded Alzheimer's disease. Neurosci Lett 1994; 174: 97–100.
   PubMed Web of Science ®Google Scholar
• Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmuller F, et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 2000; 55: 480–3.
   PubMed Web of Science ®Google Scholar
• Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, et at Association of early-onset Alzheimer's disease with an interleukin-1 alpha gene polymorphism. Ann Neurol 2000; 47: 361–5.
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, et at Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000; 47: 365–8.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Winblad B, Eikelenboom P. Inflammation and neuroimmunotrophic activity in Alzheimer's disease. Neuro gerontology & Neuro geriatrics, Vol. 2. Barcelona: Prous Science; 1998.
   Google Scholar
• Neuroinflammation Working Group: Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383–421.
   PubMed Web of Science ®Google Scholar
• Cacabeos R, Alvarez XA, Fernandez-Novoa L, Franco A, Mangues R, Pellicer A, et at Brain interleukin-113 in Alzheimer's disease and vascular dementia. Methods Find Exper Clin Pharmacol 1994; 16: 141–51.
   PubMedGoogle Scholar
• Cacabelos R, Caamario J, Gómez MJ, Fernandez-Novoa L, Franco-Maside A, Alvarez XA. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain map-ping, cerebrovascular hemodynamics, and immune factors. Ann NY Acad Sci 1996; 777: 399–403.
   PubMed Web of Science ®Google Scholar
• Alvarez XA, Fernandez-Novoa L, Caamario J, Corzo L, Zas R, Beyer K, et at Cerebrovascular changes associated with interleukin-1 beta (IL-113) and histamine (HA) levels in Alzheimer's disease. Ann NY Acad Sci 1997; 826: 375–8.
   PubMedGoogle Scholar
• Alvarez, XA, Franco A, Fernandez-Novoa L, Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 1996; 29: 237–52.
   PubMedGoogle Scholar
• Fernindez-Novoa L, Cacabelos R. Histamine function in brain disorders. Behav Brain Res 2001; 124: 213–33.
   PubMed Web of Science ®Google Scholar
• Kolsch H, Ptok U, Bagli M, Papassotiropoulos A, Schmitz S, Barlow K, et at Gene polymorphism of interleukin-1 alpha influence the course of Alzheimer's disease. Ann Neurol 2001; 49: 818–9.
   PubMed Web of Science ®Google Scholar
• Rebedc GW. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci Lett 2000; 293: 75–7.
   PubMed Web of Science ®Google Scholar
• Griffin WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE. The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk. Exp Gerontol 2000; 35: 481–7.
   PubMed Web of Science ®Google Scholar
• Murphy GM, Claassen JD, DeVoss JJ, Pascoe N, Taylor J, Tinklenberg JR, et al. Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha-889*1 allele. Neurol-ogy 2001; 56: 1595–7.
   PubMed Web of Science ®Google Scholar
• Ki CS, Na DL, Kim DK, Kim HJ, Kim PV. Lack of association of the interleukin-1 alpha gene polymorphism with Alzheimer's disease in a Korean population. Ann Neurol 2001; 49: 817–8.
   PubMed Web of Science ®Google Scholar
• McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 2001; 357: 436–9.
   PubMed Web of Science ®Google Scholar
• Collins JS, Perry RT, Watson B, Harrell LE, Acton RT, Blacker D, et at Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. Am J Med Genet 2000; 96: 823–30.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Alvarez XA, Franco-Maside A, Fernandez- Novoa L, Caamario J. Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol 1994; 16: 29–35.
   PubMedGoogle Scholar
• Combs CK, Karlo JC, Kao SC, Landreth GE. Beta-amyloid stimulation of microglia and monocytes results in TNF-alpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001; 21: 1179–88.
   PubMed Web of Science ®Google Scholar
• Dahiyat M, Cumming A, Harrington C, Wischik C, Xuereb J, Corrigan F, et at Association between Alz- heimer's disease and the N053 gene. Ann Neurol 1999; 46: 664–7.
   PubMed Web of Science ®Google Scholar
• Singleton AB, Gibson AM, McKeith IG, Ballard CA, Perry RH, Ince PO, et at Nitric oxide synthase gene polymorph- isms in Alzheimer's disease and dementia with Lewy bodies. Neurosci Lett 2001; 303: 33–6.
   PubMed Web of Science ®Google Scholar
• Kunugi H, Akahane A, Ueki A, Otsuka M, Isse K, Hirasawa H, et at No evidence for an association between the Glu298Asp polymorphism of the N053 gene and Alzheimer's disease. J Neural Transm 2000; 107: 1081–4.
   PubMed Web of Science ®Google Scholar
• Kehoe PG, Russ C, McIlroy S, Williams H, Holmans P, Holmes C, et at. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 1999; 21: 71–2.
   PubMed Web of Science ®Google Scholar
• Narain Y, Yip A, Murphy T, Brayne C, Easton D, Evans JG, et at. The ACE gene and Alzheimer's disease suscepti-bility. J Med Genet 2000; 37: 695–7.
   PubMed Web of Science ®Google Scholar
• Yang JD, Feng G, Zhang J, Lin ZX, Shen T, Breen G, et at. Association between angiotensin-converting enzyme gene and late onset Alzheimer's disease in Han Chinese. Neurosci Lett 2000; 295: 41–4.
   PubMed Web of Science ®Google Scholar
• Isbir T, Agachan B, Yilmaz H, Aydin M, Kara I, Eker D, et al. Interaction between apolipoprotein-E and angiotensin-converting enzyme geneotype in Alzheimer disease. Am J Alzheim Dis Other Dem 2001; 16: 205–10.
   PubMedGoogle Scholar
• De Olano M, Mesa MD, Fernandez-Novoa L, Corzo L, Blanco A, Cacabelos R. Angiotensin-converting enzyme I/D polymorphism and angiotensinogen M235T polymorphism in cerebrovascular pathology. Proc Int Cong Vascular Dementia. Bologna: Monduzzi Editore; 1999: 207–10.
   Google Scholar
• Zuliani G, Ble A, Zanca R, Murani MR, Zurlo A, Vavalle C, et at. Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia. Acta Neurol Scand 2001; 103: 304–8.
   PubMed Web of Science ®Google Scholar
• Farrer LA, Sherbatich T, Keryanov SA, Korovaitseva GI, Rogaeva EA, Petruk S, et at. Association between angio- tensin-converting enzyme and Alzheimer disease. Arch Neurol 2000; 57: 210–4.
   PubMedGoogle Scholar
• Chapman J, Wang N, Treves TA, Korczyn AD, Borstein NM. ACE, MTHFR, factor V Leiden, and APOE poly-morphisms in patients with vascular and Alzheimer's dementia. Stroke 1998; 29: 1401–4.
   PubMed Web of Science ®Google Scholar
• Hu J, Miyatake F, Aizu Y, Nakagawa H, Nakamura S, Tamaoka A, et at. Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese popula-tion. Neurosci Lett 1999; 277: 65–7.
   PubMed Web of Science ®Google Scholar
• Haniu M, Denis P, Young Y, Mendiaz EA, Fuller J, Hui JO, et at. Characterization of Alzheimer's beta-secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem 2000; 275: 21099–106.
   PubMed Web of Science ®Google Scholar
• Nowotny P, Kwon JM, Chakraverty S, Nowotny V, Morris JC, Goate AM. Association studies using novel polymorphisms in BACE1 and BACE2. Neuroreport 2001; 12: 1799–802.
   PubMed Web of Science ®Google Scholar
• Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al. BACE1 is the major beta-secretase for generation of A-beta peptides by neurons. Nat Neurosci 2001; 4: 233–4.
   PubMed Web of Science ®Google Scholar
• Murphy T, Yip A, Brayne C, Easton D, Evans JG, Xuereb J, et al. The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease. Neuroreport 2001; 12: 631–4.
   PubMed Web of Science ®Google Scholar
• Bodendorf U, Fischer F, Bodian D, Multhaup G, Paganetti P. A. Splice variant of beta-secretase deficient in the amyloidogenic processing of the amyloid precursor protein. J Biol Chem 2001; 276: 12019–23.
   PubMed Web of Science ®Google Scholar
• Dominguez DI, De Strooper B, Annaert W. Secretases as therapeutic targets for the treatment of Alzheimer's disease. Amy/oid 2001; 8: 124–42.
   PubMed Web of Science ®Google Scholar
• Balhin M, Abrahamson M. Sstll polymorphic sites in the promoter region of the human cystatin C gene. Hum Genet 1991; 87: 751–2.
   PubMed Web of Science ®Google Scholar
• Abrahamson M, Islam MQ, Szpirer J, Szpirer C, Levan G. The human cystatin C gene (CST3), mutated in hereditary cystatin C amyloid angiopathy, is located on chromosome 20. Hum Genet 1989; 82: 223–6.
   PubMed Web of Science ®Google Scholar
• Finckh U, von der Kammer H, Velden J, Michel T, Andresen B, Deng A, et al. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol 2000; 57: 1579–83.
   PubMedGoogle Scholar
• Crawford FC, Freeman MI Schinka JA, Abdullah LI, Richards D, Sevush S, et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 2000; 55: 763–8.
   PubMed Web of Science ®Google Scholar
• Maruyama H, Izumi Y, Oda M, Toni T, Morino H, Toji H, et al. Lack of association between cystatin C gene polymorphisms in Japanese patients with Alzheimer's dis-ease. Neurology 2001; 57: 337–9.
   PubMed Web of Science ®Google Scholar
• Nishiyama M, Kato Y, Hashimoto M, Yukawa S, Omori K. Apolipoprotein E, methylenetetrahydrofolate reductase (MTHFR) mutation and the risk of senile dementia - an epidemiological study using the polymerase chain reaction (PCR) method. J Epidemiol 2000; 10: 163–72.
   PubMedGoogle Scholar
• Pollak RD, Pollak A, Idelson M, Bejarano-Achache Doron D, Blumenfeld A. The C6/71 mutation in the methylenetetrahydrofolaw reductase (MTHFR) gene and vascular dementia. J Am Geriat Soc 2000; 48: 664–8.
   PubMed Web of Science ®Google Scholar
• Lin F-H, Lin R, Wisniewski HM, Hwang YW, Grundke- Iqbal I, Healey-Louie G, et al. Detection of point mutations in codon 331 of mitochondrial NADH dehydrogenase subunit 2 in Alzheimer's brains. Biochem Biophys Res Commun 1992; 182: 238–46.
   PubMed Web of Science ®Google Scholar
• Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, Ueki A, et at Deficiency of mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochem Biophys Res Commun 2000; 273: 192–6.
   PubMed Web of Science ®Google Scholar
• Chang SW, Zhang D, Chung HD, Zassenhaus HP. The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain. Biochem Biophys Res Commun 2000; 273: 203–8.
   PubMed Web of Science ®Google Scholar
• Wallace DC, Stugard C, Murdock D, Schurr T, Brown MD. Ancient mtDNA sequences in the human nuclear genome: a potential source of error in identifying pathogenic mutations. Proc Natl Acad Sci USA 1997; 94: 14900–5.
   PubMed Web of Science ®Google Scholar
• Tysoe C, Robinson D, Brayne C, Dening T, Paykel ES, Huppert FA, et at The tRNA(G1n) 4336 mitochondrial DNA variant is not a high penetrance mutation which predisposes to dementia before the age of 76 years. J Med Genet 1996; 33: 1002–6.
   PubMed Web of Science ®Google Scholar
• Carrieri G, Bonafe M, De Luca M, Rose G, Varcasia 0, Bruni A, et al. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum Genet 2001; 108: 194–8.
   PubMed Web of Science ®Google Scholar
• Qiu X, Chen y, Zhou M. Two point mutations in mitochondrial DNA of cytochrome c oxidase coexist with normal mtDNA in a patients with Alzheimer disease. Brain Res 2001; 893: 261–3.
   PubMed Web of Science ®Google Scholar
• Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Bau S, et al. Evidence for genetic linkage to Alzheimer's disease to chromosome 10q. Science 2000; 290: 2302–3.
   PubMed Web of Science ®Google Scholar
• Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Adamson J, Schaid DJ, et al. Linkage of plasma A-beta- 42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 2000; 290: 2303–4.
   PubMed Web of Science ®Google Scholar
• Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 2000; 290: 2304–5.
   PubMed Web of Science ®Google Scholar
• Pericalc-Vance MA, Bebout JL, Gaskell PC, Yamaoka LH, Hung WY, Alberts M, et at Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet 1991; 48: 1034–50.
   PubMed Web of Science ®Google Scholar
• Russ C, Lovestone S, Powell F. Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol Psychiatry 2001; 6: 320–4.
   PubMed Web of Science ®Google Scholar
• Matsubara M, Yamagata H, Kamino K, Nomura T, Kohara K, Kondo M, et al. Genetic association between Alzheimer disease and the alpha-synuclein gene. Dement Geriat Cogn Disord 2001; 12: 106–9.
   PubMed Web of Science ®Google Scholar
• Schafer AJ, Hawkins JR. DNA variation and the future of human genetics. Nat Biotechnol 2001; 16: 33–9.
   Google Scholar
• Isalcsson A, Landegren U, Syvanen AC, Bork P, Stein C, Ortigao F, et al. Discovery, scoring and utilization of human single nucleotide polymorphisms: a multidisciplinary prob-lem. Eur J Hum Genet 2000; 8: 154–6.
   PubMedGoogle Scholar
• Petronis A. Human morbid genetics revisited: relevance of epigenetics. Trends Genet 2001; 17: 142–6.
   PubMed Web of Science ®Google Scholar
• Chadwick DJ, Cardew G. Epigenetics. Novartis Founda- tion. Chichester: Wiley; 1998.
   Google Scholar
• Wolfe AP, Matzke mA. Epigenetics: regulation through repression. Science 1999; 286: 481–6.
   PubMed Web of Science ®Google Scholar
• Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293: 1068–70.
   PubMed Web of Science ®Google Scholar
• Matzke M, Matzke AJ, Kooter JM. RNA: Guiding gene silencing. Science 2001; 293: 1080–3.
   PubMed Web of Science ®Google Scholar
• Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GI Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 2001; 293: 1146–50.
   PubMed Web of Science ®Google Scholar
• Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405: 837–46.
   PubMed Web of Science ®Google Scholar
• Husi H, Grant, SGN. Proteomics of the nervous system. Trends Neurosci 2001; 24: 259–66.
   PubMed Web of Science ®Google Scholar
• Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000; 405: 827–36.
   PubMed Web of Science ®Google Scholar
• Biissow K, Konthur Z, Lueking A, Lehrach H, Walter G. Protein array technology. Potential use in medical diagnosis. Am J Pharmacogenomics 2001; 1: 37–43.
   PubMedGoogle Scholar
• Peltonen L, McKusick VA. Dissecting human disease in the postgenomic era. Science 2001; 291: 1224–9.
   PubMed Web of Science ®Google Scholar
• McGuffin P, Riley R. Plomin D. Toward behavioural genomics. Science 2001; 291: 1232–3.
   PubMed Web of Science ®Google Scholar
• Brown PO, Hartwell L. Genomics and human disease - variations on variation. Nat Genet 1998; 18: 91–3.
   PubMed Web of Science ®Google Scholar
• Laurence D, Carpenter J. A dictionary of pharmacology and allied topics. 2nd ed. Amsterdam: Elsevier; 1998.
   Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–91.
   PubMed Web of Science ®Google Scholar
• Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999; 56: 247–58.
   PubMed Web of Science ®Google Scholar
• Danesi R, De Braud F, Fogli S, Di Paolo A, Del Tacca M. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol Sci 2001; 22: 420–6.
   PubMed Web of Science ®Google Scholar
• March R. Pharmacogenomics: the genomics of drug re-sponse. Yeast 2000; 17: 16–21.
   PubMed Web of Science ®Google Scholar
• Emilien G, Ponchon M, Caldas C, Isacson Q, Maloteaux W. Impact of genomics on drug discovery and clinical medicine. QJM 2000; 93: 391–423.
   PubMed Web of Science ®Google Scholar
• Peet NP, Bey P. Pharmacogenomics: challenges and oppor-tunities. Drug Discov Today 2001; 6: 495–8.
   PubMed Web of Science ®Google Scholar
• Götz J. Tau and transgenic animal models. Brain Res Brain Res Rev 2001; 35: 266–86.
   PubMedGoogle Scholar
• Huber G, Marz W, Martin JR, Malherbe P, Richards JG, Sueoka N, et at. Characterization of transgenic mice ex-pressing apolipoprotein E4(C112R) and apolipoprotein E4(L28P;C112R). Neuroscience 2000; 101: 211–8.
   PubMed Web of Science ®Google Scholar
• Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG,Chen KS, et at. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10: 1317–24.
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E. Genetically altered transgenic models of Alzheimer's disease. J. Neural Transm 2000; 59(Suppl.): 175–83.
   Web of Science ®Google Scholar
• Gallagher M, Rapp PR. The use of animal models to study the effects of aging on cognition. Annu Rev Psychol 1997; 48: 339–70.
   PubMed Web of Science ®Google Scholar
• McDonald MP, Overmier B. Present imperfect: A critical review of animal models of the mnemonic impairments in Alzheimer's disease. Neurosci Biobehav Rev 1998; 22: 99–120.
   PubMed Web of Science ®Google Scholar
• Harris S. Transgenic knockouts as part of high-throughput, evidence-based target selection and validation strategies. Drug Discov Today 2001; 6: 628–36.
   PubMed Web of Science ®Google Scholar
• Maneiro E, Lombardi VRM, Cacabelos R. Rat cell cultures: experimental models to study neurodegenerative disorders and new pharmacological compounds. Methods Find Exp Clin Pharmacol 1996; 18: 615–45.
   PubMedGoogle Scholar
• Maneiro E, Lombardi VRM, Lagares R, Cacabelos R. An experimental model to study the cytotoxic effects induced by 13-amyloid, histamine, LPS and serum from Alzheimer patients on cultured rat endothelial cells. Methods Find Exp Clin Pharmacol 1997; 19: 5–12.
   Google Scholar
• Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualizatim of psychiatric treatment. Am J Pharma- cogenomics 2001; 1: 3–10.
   PubMedGoogle Scholar
• Alvarez XA, Mouzo R, Pichel V, Perez P, Laredo M, Fernandez-Novoa L, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity, and cerebral perfusion. Methods Find Exp Clin Pharmacol 1999; 21: 633–44.
   PubMedGoogle Scholar
• Alvarez XA, Pichel V, Perez P, Laredo M, Corzo L, Zas R, et at. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Methods Find Exp Clin Pharmacol 2000; 22: 585–94.
   PubMedGoogle Scholar
• Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA, et al. The role of apolipo-protein E in Alzheimer's disease: pharmacogenomic target selection. Biochim Biophys Acta 2000; 1502: 85–94.
   PubMed Web of Science ®Google Scholar
• Rioux PP. Clinical trials in pharmacogenetics and pharma- cogenomics: methods and applications. Am J Health Syst Pharm 2000; 57: 899–901.
   Web of Science ®Google Scholar
• Robertson JA. Consent and privacy in pharmacogenetic testing. Nat Genet 2001; 28: 207–9.
   PubMed Web of Science ®Google Scholar
• Issa A1'1 Ethical considerations in clinical pharmacoge- nomics research. Trends Pharmacol Sci 2000; 21: 247–9.
   PubMed Web of Science ®Google Scholar